Does vitamin D improve markers of vascular health in stroke patients?
Not Applicable
Completed
- Conditions
- StrokeCirculatory System
- Registration Number
- ISRCTN28737567
- Lead Sponsor
- niversity of Dundee (UK)
- Brief Summary
1. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/21194910
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 68
Inclusion Criteria
1. Clinical diagnosis of completed stroke (ischaemic or haemorrhagic)
2. Serum 25-hydroxy vitamin D level less than 50 nmol/
Exclusion Criteria
1. Hyper- or hypocalcaemia
2. Metastatic malignancy
3. Liver function tests over three times limit of normal
4. Estimated glomerular filtration rate (GFR) less than 40 ml/min
5. Previous clinical diagnosis of osteomalacia
6. Taking vitamin D preparations
7. Unable to give written informed consent
8. Unable to swallow tablets orally
9. Atrial fibrilation (to provide a more homogeneous aetiology)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood pressure (seated office and 24 hour measurements) (added 26/02/2018: measured using a blood pressure cuff) at baseline, 8 and 16 weeks after vitamin D administration.
- Secondary Outcome Measures
Name Time Method Current secondary outcome measures (as of 26/02/2018):<br>All outcomes are measured at baseline, and 8 and 16 weeks after vitamin D administration:<br>1. Endothelial function of the artery in the arm is measured using ultrasound following an inflated blood pressure cuff <br>2. B-type natriuretic peptide is measured from a blood sample <br>3. Heart rate variability is measured using a 24 hour ECG<br>4. Vitamin D deficiency is measured using 25OHD <br><br>Previous secondary outcome measures;<br>The secondary outcomes will also be measured at baseline and then at 8 and 16 weeks after vitamin D administration.<br><br>1. Endothelial function<br>2. B-type natriuretic peptide<br>3. Heart rate variability